Pharmaceuticals

Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data

Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data

Why Is Bone Biologics Stock Surging On Friday?

Why Is Bone Biologics Stock Surging On Friday?

What's Going On With Viking Therapeutics Stock On Wednesday?

What's Going On With Viking Therapeutics Stock On Wednesday?

Why Is Bone Biologics Stock Surging On Friday?

Why Is Bone Biologics Stock Surging On Friday?

What's Going On With Viking Therapeutics Stock On Wednesday?

What's Going On With Viking Therapeutics Stock On Wednesday?

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

Pharmaceuticals Recent News

What's Going On With Verastem Oncology Stock On Monday?

What's Going On With Verastem Oncology Stock On Monday?

Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses.

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025.

Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?

Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?

Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.

GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion

GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure

Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure

Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwinds and currency impacts.

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

Aurinia posts Q1 profit and 25% LUPKYNIS sales growth, reports $62.47 million revenue, and reaffirms full-year guidance.

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

Cencora raised its 2025 earnings forecast after a strong Q2 driven by U.S. drug sales, though total revenue of $75.5 billion slightly missed expectations.

Sarepta Therapeutics Stock Plummets After Q1 Results: Here's Why

Sarepta Therapeutics Stock Plummets After Q1 Results: Here's Why

Sarepta Therapeutics shares are sinking after the company releases its first-quarter results after Tuesday's closing bell. Here's a look at the details from the report.

Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance

Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs.

Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed

Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed

Amneal Pharmaceuticals reported first-quarter 2025 adjusted earnings per share of 21 cents, up from 14 cents a year ago.

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?

Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?

Eli Lilly reports 1Q earnings on Thursday, with EPS of $3.05 and revenues of $12.67 billion expected. Stock is up 14.35% in past year.

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products.

AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst

AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst

Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?

Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?

Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock over past year, analysts see ~30% upside potential.

Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence

Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1.

Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely

Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and potential upside surprises.